ChemAxon Ltd. Announces New CEO and Head of R&D

ChemAxon Ltd. Announces New CEO and Head of R&D
5/12/2008

BUDAPEST, Hungary, May 12 /PRNewswire/ -- ChemAxon, a software solutions provider for cheminformatics, today announced the appointment of Alex Drijver as CEO. The arrival signals the companies increased focus on business development and market position. Ferenc Csizmadia, founder and former CEO, moves to Chairman and Head of Research and Development. The new R&D position formalises the bridge between the customer base and the company's development strategy and in particular the next generation of products under launch.

Alex joins ChemAxon with over 20 years international commercial experience, most recently as CEO and CFO of ThalesNano Inc, a Budapest based manufacturer of novel microfluidic based instruments for chemical synthesis, and CFO of ComGenex, Inc., a chemistry services provider now part of Albany Molecular.

About ChemAxon

ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information please visit http://www.chemaxon.com.

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.